Skip to content
HowShorted

Editas Medicine, Inc. short interest in 2021

In 2021, Editas Medicine, Inc.'s disclosed short interest ran from 15.24% of shares outstanding on 15 Jan 2021 to 16.67% on 31 Dec 2021, a change of +1.43 percentage points. The year's high was 16.80% on 26 Feb 2021 and its low 9.92% on 31 Aug 2021, averaging 14.25% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.18 days on 28 May 2021. Full history: Editas Medicine, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Editas Medicine, Inc. in 2021

2021 in figures

Start of year
15.24% (15 Jan 2021)
End of year
16.67% (31 Dec 2021)
Change
+1.43 pp
High
16.80% (26 Feb 2021)
Low
9.92% (31 Aug 2021)
Average
14.25%
Highest days to cover
13.18 (28 May 2021)
SEC filings marked
9

Every report in 2021

Editas Medicine, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.24%3.69
29 Jan 202114.47%2.68results (8-K)
12 Feb 202115.79%4.11
26 Feb 202116.80%4.91results (8-K), 10-K filed
15 Mar 202115.76%4.40
31 Mar 202115.16%6.49
15 Apr 202115.22%9.31
30 Apr 202115.37%6.72
14 May 202115.53%8.76results (8-K), 10-Q filed
28 May 202115.66%13.18
15 Jun 202115.29%8.99
30 Jun 202115.38%3.20
15 Jul 202112.28%3.56
30 Jul 202112.44%8.26
13 Aug 202110.98%3.01results (8-K), 10-Q filed
31 Aug 20219.92%4.93
15 Sep 202110.25%4.42
30 Sep 202110.11%2.75
15 Oct 202114.88%5.80
29 Oct 202114.61%11.31
15 Nov 202113.95%8.71results (8-K), 10-Q filed
30 Nov 202114.43%9.53
15 Dec 202115.83%6.70
31 Dec 202116.67%7.24

See also: Editas Medicine, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.